Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study

This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.

OUTLINE: This is a multi-center study.

Sample Collection:

• Tumor sample
• Serum sample

Treatment Regimen:

• All registered patients must be planning treatment with lonafarnib

Inclusion Criteria:

• Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
• Age > 18 years.
• Planned treatment with lonafarnib for metastatic breast cancer.
• Must consent to have a biopsy performed to obtain fresh tissue or be able to identify a formalin fixed paraffin embedded (FFPE) tissue block in which tumor samples can be obtained to complete the testing for this study.

Exclusion Criteria:

• Planned treatment with any other treatment regimen